ArticleMobile DNA2014
Development of a monoclonal antibody specific to the endonuclease domain of the human LINE-1 ORF2 protein.
Article in Mobile DNA, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Variation in LINE-1 ORF1p expression across histologic and demographic subgroups in non-small cell lung cancers.Translational oncology · 2026Article
- Detection of endogenous LINE-1 ORF2p and its potent reverse transcriptase activity in the MCF-7 breast cancer cell line.The FEBS journal · 2026Article
- Functional analyses identify the L1 ORF2p Cryptic domain as a hub for intramolecular interfaces required for retrotransposition.Nucleic acids research · 2026Article
- Article
- Article
- Article
- Schlafen-5 inhibits LINE-1 retrotransposition.iScience · 2023Article
- LINE-1 Cargo and Reverse Transcriptase Activity Profiles in Extracellular Vesicles from Lung Cancer Cells and Human Plasma.International journal of molecular sciences · 2022Article
- Robust expression of LINE-1 retrotransposon encoded proteins in oral squamous cell carcinoma.BMC cancer · 2021Observational
- LINE-1 ORF2p expression is nearly imperceptible in human cancers.Mobile DNA · 2020Article
- Article
- Properties of LINE-1 proteins and repeat element expression in the context of amyotrophic lateral sclerosis.Mobile DNA · 2018Article
- Transposable elements in cancer.Nature reviews. Cancer · 2017Review
- Truncated ORF1 proteins can suppress LINE-1 retrotransposition in trans.Nucleic acids research · 2017Article
- Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation.Oncotarget · 2016Article
- The endonuclease domain of the LINE-1 ORF2 protein can tolerate multiple mutations.Mobile DNA · 2016Article
- The importance of L1 ORF2p cryptic sequence to ORF2p fragment-mediated cytotoxicity.Mobile genetic elementsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLINE-1 (L1) retrotransposons are common occupants of mammalian genomes representing about a fifth of the genetic content. Ongoing L1 retrotransposition in the germ line and somatic tissues has contributed to structural genomic variations and disease-causing mutations in the human genome. L1 mobilization relies on the function of two, self-encoded proteins, ORF1 and ORF2. The ORF2 protein contains two characterized domains: endonuclease and reverse transcriptase.
resultsUsing a bacterially purified endonuclease domain of the human L1 ORF2 protein, we have generated a monoclonal antibody specific to the human ORF2 protein. We determined that the epitope recognized by this monoclonal antibody includes amino acid 205, which is required for the function of the L1 ORF2 protein endonuclease. Using an in vitro L1 cleavage assay, we demonstrate that the monoclonal anti-ORF2 protein antibody partially inhibits L1 endonuclease activity without having any effect on the in vitro activity of the human AP endonuclease.
conclusionsOverall, our data demonstrate that this anti-ORF2 protein monoclonal antibody is a useful tool for human L1-related studies and that it provides a rationale for the development of antibody-based inhibitors of L1-induced damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.